GlobeNewswire Inc | Sep 7, 2021 04:30PM EDT

September 07, 2021

BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AzurRx or the Company) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemictherapies forgastrointestinal (GI) diseases, today announced that James Sapirstein, Chief Executive Officer of AzurRx, will presentvirtually atthe H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The prerecorded presentation will be available starting at 9:00 a.m. ET on September 13, 2021 and can be accessed via the conferences virtual platform by registered conference attendees.

During the presentation, Mr. Sapirstein will provide an overview of AzurRxs business and clinical development programs and discuss anticipated 2021 and early 2022 milestones. Additionally, Mr. Sapirstein and members of the AzurRx management team will participate in virtual one-on-one meetings with registered investors and pharmaceutical company executives.

Details of the presentation are as follows:

Event: H.C. Wainwright 23rd Annual Global Investment ConferenceDate: September 13-15, 2021Time: Presentations available starting at: 9:00 a.m. ET on September 13, 2021Registration: https://journey.ct.events/view/ 01277a2b-679b-4186-8ed2-5fbcc0152af2

About AzurRx BioPharma, Inc.AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of two gut-restricted GI assets in three clinical indications. The lead therapeutic candidate is MS1819, a recombinant lipase developed for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. AzurRx is also advancing two clinical programs using proprietary formulations of niclosamide, a small molecule with anti-viral and anti-inflammatory properties: FW-1022, for COVID-19 gastrointestinal infections and FW-420, for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients. The Company is headquartered in Boca Raton, Florida with clinical operations in Hayward, California. For more information visit www.azurrx.com.

Forward-Looking StatementThis press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Companys actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; the size of the potential markets for the Companys drug candidates and its ability to service those markets; and the Companys current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Companys financial results are contained in the Companys Annual Report on Form 10-K for the year ended December 31, 2020 under the heading Risk Factors, as well as the Companys subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information:AzurRx BioPharma, Inc.777 Yamato Road, Suite 502Boca Raton, FL 33431Phone: (561) 589-7020info@azurrx.com

Media contact:Tiberend Strategic Advisors, Inc.Johanna Bennett / David Schemelia(212) 375-2665 / (609) 468-9325jbennett@tiberend.com / dschemelia@tiberend.com